

January 28, 2015

Attention: Physicians, Nurse Practitioners, Walk-in Clinics, Hospitals – Administration, Emergency, Infection Control, Occupational Health; Long-Term Care Homes, Retirement Homes, Correctional Services, EMS

*** CORRECTION ***

RE: Updates to Ontario's Immunization Program

Effective immediately, the following changes will be made to Ontario's publicly funded immunization programs as listed below:

***Adult Pertussis Immunization: ***

- *All adults 18 years of age and older, including those 65 years of age and older, are now eligible to receive a single publicly funded dose of the pertussis containing vaccine (Tdap), irrespective of receiving a prior dose of Tdap in adolescence. This adult dose of pertussis-containing vaccine replaces one of the Td booster doses, which is given every 10 years.*

High Risk Meningococcal Immunization:

- High risk Meningococcal Conjugate ACYW-135 immunization program now includes individuals with HIV and persons with acquired complement deficiency. This high risk program will now include an age-appropriate primary series followed by booster doses according to the attached schedule for high risk individuals.
- Introducing a new high risk meningococcal serogroup B immunization program for individuals 2 months of age through 17 years who meet one or more of the following criteria: close contact with a case of invasive - meningococcal disease (IMD) caused by serogroup B or at risk of an IMD outbreak caused by serogroup B; and individuals with specific underlying medical conditions, according to the attached schedule for high risk individuals.

High Risk Pneumococcal Conjugate Immunization:

- A dose of pneumococcal conjugate vaccine, in addition to the existing pneumococcal polysaccharide vaccine is recommended to the following high risk adults aged 50 years and older: adults with hematopoietic stem cell transplants, adults with HIV, adults with immunosuppressive conditions.

More information on these immunization program enhancements – including supporting materials – is available on the ministry's website at <http://www.health.gov.on.ca/en/pro/programs/immunization/resources.aspx>. An addendum to the Publicly Funded Immunization Schedules for Ontario to reflect the changes is attached. An updated schedule will be made available in early 2015.

To order vaccine, please complete the attached order forms.

If you have any questions, please call 1-866-888-4577 and ask for ext. 1507.

Haliburton
705-457-1391

Lindsay
705-324-3569

Port Hope
905-885-9100

After Hours
1-888-255-7839

Updates to the Publicly Funded Immunization Schedules for Ontario

This addendum incorporates the immunization program enhancements that have been announced by the Ministry of Health and Long-Term Care starting December 2014. This addendum can be attached to the existing Publicly Funded Immunization Schedules for Ontario (dated August 2011) until the Schedules are revised to reflect these program updates. The following tables outline the vaccine program enhancements and schedule updates:

Multicomponent Meningococcal B [4CMenB] (Bexsero®) program for high risk children aged 2 months to 17 years			
Eligibility Criteria	<ul style="list-style-type: none"> Individuals with functional or anatomic asplenia Individuals with complement, properdin, factor D or primary antibody deficiencies Cochlear implant recipients (pre/post implant) Individuals with acquired complement deficiencies (e.g., receiving eculizumab) Individuals with HIV 		
Vaccine Intervals	Age at first dose	Recommended Intervals	Minimum Intervals
	2-5 months	1 st dose 2 nd dose, 2 months after 1 st dose 3 rd dose, 2 months after 2 nd dose 4 th dose, 2 months after 3 rd & at age ≥12 months	1 st dose 2 nd dose, 4 weeks after 1 st dose 3 rd dose, 4 weeks after 2 nd dose 4 th dose, 8 weeks after 3 rd dose & at age ≥12 months
	6-11 months	1 st dose 2 nd dose, 2 months after 1 st dose 3 rd dose, 2 months after 2 nd dose & at age ≥12 months	1 st dose 2 nd dose, 8 weeks after 1 st dose 3 rd dose, 8 weeks after 2 nd dose & at age ≥12 months
	12 months to 10 years	1 st dose 2 nd dose, 2 months after 1 st dose	1 st dose 2 nd dose, 8 weeks after 1 st dose
	11 to 17 years	1 st dose 2 nd dose, 1 month after 1 st dose	1 st dose 2 nd dose, 4 weeks after 1 st dose

Meningococcal Conjugate ACYW-135 [Men-C-ACYW] (Menactra®) program for high risk individuals 9 months to 55 years of age			
Eligibility Criteria	<ul style="list-style-type: none"> Individuals with functional or anatomic asplenia Individuals with complement, properdin, factor D or primary antibody deficiencies Cochlear implant recipients (pre/post implant) Individuals with acquired complement deficiencies (e.g., receiving eculizumab) Individuals with HIV 		
Vaccine Intervals	Age at first dose	Recommended Intervals	Minimum Intervals
	9 to 11 months	1 st dose 2 nd dose, 2 months after 1 st dose 3 rd dose, 2 months after 2 nd dose Booster doses every 3 to 5 years	1 st dose 2 nd dose, 4 weeks after 1 st dose 3 rd dose, 4 weeks after 2 nd dose 4 th dose, 4 weeks after 3 rd dose and at age ≥12 months <i>(Note: 4th dose is not required if 3rd dose is given at age ≥ 12 months and ≥ 4 weeks after 3rd dose)</i> Booster doses every 3 to 5 years
	12 months to 6 years	1 st dose 2 nd dose, 2 months after 1 st dose Booster doses every 3 to 5 years	1 st dose 2 nd dose, 4 weeks after 1 st dose Booster doses every 3 to 5 years
Notes	7 to 55 years	1 st dose 2 nd dose, 2 months after 1 st dose Booster doses every 5 years	1 st dose 2 nd dose, 4 weeks after 1 st dose Booster doses every 5 years
	<ul style="list-style-type: none"> At least 4 weeks is required between doses of Men-C-ACYW and Men-C-C At least 5 years is required between doses of Men-C-ACYW and Men-P-ACYW for adults ≥55 years of age who have already received Men-C-ACYW 		

Pneumococcal Conjugate 13 [Pneu-C-13] (Pneumovax® 13) program for high risk individuals ≥50 years of age

Eligibility Criteria	<ul style="list-style-type: none"> • Individuals who have undergone Hematopoietic stem cell transplants (HSCT) (3 doses) – See below for schedule and dosing intervals • Individuals with HIV (1 dose) • Individuals with other immunocompromising conditions including (1 dose): <ul style="list-style-type: none"> ○ Asplenia (anatomical or functional) ○ Sickle cell disease or other hemoglobinopathies ○ Congenital immunodeficiencies involving any part of the immune system, including B lymphocyte (humoral) immunity, T-lymphocyte (cell) mediated immunity, complement system (properdin, or factor D deficiencies), or phagocytic functions ○ Immunosuppressive therapy including use of long term corticosteroids, chemotherapy, radiation therapy, post-organ-transplant therapy, biologic and non-biologic immunosuppressive therapies for rheumatologic and other inflammatory diseases ○ Malignant neoplasms including leukemia and lymphoma ○ Solid organ or islet cell transplant (candidate or recipient) 	
Vaccine Intervals for HSCT recipients	Recommended Intervals	Minimum Intervals
	<p>1st dose 2nd dose, 1 month after 1st dose 3rd dose, 1 month after 2nd dose</p>	<p>1st dose 2nd dose, 4 weeks after 1st dose 3rd dose, 4 weeks after 2nd dose</p>
Notes	<ul style="list-style-type: none"> • 1 dose of Pneu-P-23 should be given at least 8 weeks after the last dose of Pneu-C-13 (except for HSCT recipients who should start series 3 to 9 months after transplant; 1 dose of Pneu-P-23 should be given 12 to 18 months post-transplant [6 to 12 months after last dose of Pneu-C-13]) • Alternatively if Pneu-P-23 has already been received, 1 dose of Pneu-C-13 should be given at least 1 year after the last dose of Pneu-P-23 	

Pertussis (Tdap) program for adults ≥18 years of age

Eligibility Criteria	<ul style="list-style-type: none"> • A publicly funded dose of Tdap is provided for all adults 18 years of age and older (including those aged 65 and older) • Additionally, adults are eligible regardless of whether Tdap was received in adolescence
Vaccine Intervals	<ul style="list-style-type: none"> • Adults who have not previously received Tdap vaccine at ≥18 years of age are eligible to receive 1 Tdap booster dose in lieu of their Td booster • However if the Tdap booster dose is required earlier, they are eligible to receive 1 dose of Tdap vaccine regardless of the interval since the last dose of tetanus or diphtheria containing vaccine

Replacement of DTaP-IPV with Tdap-IPV

Eligibility Criteria	<ul style="list-style-type: none"> • In May 2012, Tdap-IPV vaccine replaced DTaP-IPV vaccine for the 4-6 year booster dose that follows the primary childhood series for immunization against diphtheria, tetanus, pertussis and polio • Where DTaP-IPV are indicated in Schedules 1 and 2, replace with Tdap-IPV
-----------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------